Celcuity (NasdaqCM:CELC) has seen a remarkable surge in its price target, which now stands at 27.95 per share. This reflects a notable 12.99% increase from the previous estimate of 24.74 as of January 16, 2024.
Analysts have provided a range of targets for Celcuity, with the lowest at 20.20 and the highest at 42.00 per share. The average price target indicates an impressive 82.19% rise from the latest closing price of 15.34 per share.
The Pulse of Investment
The financial world is abuzz with activity surrounding Celcuity, as 152 funds or institutions are reporting positions in the company. This marks an uptick of 6 owners or 4.11% in the last quarter. The average portfolio weight dedicated to CELC by all funds is now at 0.11%, reflecting a substantial 19.60% increase. Institutional investors have boosted their holdings by 13.32% over the past three months, amounting to 17,950K shares.
The put/call ratio of CELC stands at 0.42, painting a bullish outlook for the company’s future.
Insider Insights
Soleus Capital Management holds 2,179K shares, representing 8.64% ownership of Celcuity. Their recent filing shows an increase from 2,056K shares, signaling a rise of 5.64%. The firm has notably ramped up its portfolio allocation in CELC by an impressive 103.18% in the last quarter.
VR Adviser owns 1,886K shares, equal to a 7.47% stake in Celcuity. Their previous filing reported 2,105K shares, indicating a decrease of 11.66%. The firm reduced its portfolio allocation by 6.99% over the last quarter.
Commodore Capital possesses 1,755K shares, amounting to 6.95% of the company. Their prior filing listed 1,694K shares, showing an increase of 3.45%. The firm spiked its portfolio allocation by 23.42% in Q4.
Perceptive Advisors hold 1,481K shares, representing a 5.87% stake in Celcuity.
Ra Capital Management owns 1,400K shares, equivalent to a 5.55% stake in the company, with no change in the last quarter.
Journey through Celcuity
Celcuity, a clinical stage biotechnology company based in Minneapolis, MN, is on a quest to transform cancer treatment landscapes. Their revolutionary diagnostic platform, CELsignia, decodes complex cellular activities in living tumor cells, unlocking new frontiers in cancer detection and treatment. Unlike traditional molecular diagnostics, Celcuity’s approach unveils previously undetectable cancer sub-types.
Fueling innovations in patient care and redefining targeted therapy patient populations for pharmaceutical companies, Celcuity is at the vanguard of medical advancement in the oncology sphere.
Fintel serves as a comprehensive investing research platform catering to individual investors, traders, financial advisors, and small hedge funds, offering a wealth of data and analysis across global markets.
Curious to delve deeper? Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
